(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

US pharma major AbbVie (NYSE: ABBV) today announced positive top-line results from its Phase III TEMPLE multicenter, ...

This was the stock's third consecutive day of losses.

In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.

Shares of AbbVie (ABBV) were in the spotlight on Wednesday after the company announced positive results from a late-stage ...

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a ...

Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a ...

Bavarian Nordic has sold a PRV for $160m, a day after the FDA announced a new scheme utilising the fast-track tickets.